Regulated trials - Revision history

Lawrence: /* Bibliography */

2025-06-04T13:27:49Z

Bibliography

← Older revision		Revision as of 13:27, 4 June 2025
Line 40:		Line 40:

	{\| class="wikitable"		{\| class="wikitable"
	! Phase !! Objective !! Sample Size !! Key Features		! Phase !! Objective !! [[Sample size\|Sample Size]] !! Key Features
	\|-		\|-
	\| Phase 1 \|\| Safety & Dosage \|\| 20–100 participants \|\| First-in-human studies, dose escalation, pharmacokinetics		\| Phase 1 \|\| Safety & Dosage \|\| 20–100 participants \|\| First-in-human studies, dose escalation, pharmacokinetics
Line 82:		Line 82:

	Regulated clinical trials are essential for ensuring the safety, efficacy, and quality of medical interventions. They play a critical role in advancing evidence-based healthcare while protecting public health. Although these trials are complex, costly, and time-consuming, they are foundational to drug and device development and remain the gold standard for regulatory approval.		Regulated clinical trials are essential for ensuring the safety, efficacy, and quality of medical interventions. They play a critical role in advancing evidence-based healthcare while protecting public health. Although these trials are complex, costly, and time-consuming, they are foundational to drug and device development and remain the gold standard for regulatory approval.

			----

	----		----
Line 87:		Line 89:
	=== Bibliography ===		=== Bibliography ===

	# ~~Schulz KF, Grimes DA~~. ~~Generation of allocation sequences in randomised trials: chance, not choice~~. ~~''The Lancet''~~. ~~2002;359~~(~~9305~~):~~515–519~~.		# U.S. Food and Drug Administration (FDA). CFR Title 21: Food and Drugs – Part 312: Investigational New Drug Application (IND). Available from: https://www.ecfr.gov
	# ~~Altman DG, Bland JM~~. ~~Statistics notes: how to randomise~~. ~~''BMJ''. 1999;319~~(~~7211~~)~~:703–704~~.		# European Medicines Agency (EMA). Guideline for Good Clinical Practice E6(R2). International Council for Harmonisation (ICH); 2016. EMA/CHMP/ICH/135/1995.
	# ~~Moher D, Hopewell~~ S~~, Schulz KF, et al~~. ~~[[CONSORT]] 2010 explanation~~ and ~~elaboration: updated guidelines for reporting parallel group randomised trials~~. ~~''BMJ''~~. ~~2010;340~~:~~c869~~.		# U.S. Food and Drug Administration (FDA). Clinical Trials Guidance Documents. Available from: https://www.fda.gov
	# ~~Piantadosi S~~. Clinical ~~Trials: A Methodologic Perspective~~. ~~3rd ed. Wiley~~; ~~2017~~. ~~Chapter 7~~: ~~[[Randomization]] methods and implementation~~.		# ICH E8(R1). General Considerations for Clinical Studies. International Council for Harmonisation; 2019. Available from: https://www.ich.org
	# ~~Higgins JPT~~, ~~Thomas J, Chandler J, et al~~. ~~(editors)~~. ~~Cochrane Handbook for Systematic~~ Reviews ~~of Interventions, version 6~~.3 (~~updated February 2022~~)~~. Cochrane; 2022. Chapter 8~~: ~~Random sequence generation and [[allocation concealment]]~~.		# Getz KA, Campo RA. New benchmarks for the clinical trial enterprise: the changing landscape of clinical trial activity in the U.S. ''Nature Reviews Drug Discovery''. 2017;16(5):307–308.

	----		----
	''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''		''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence: /* Conclusion */

2025-06-04T13:27:02Z

Conclusion

← Older revision		Revision as of 13:27, 4 June 2025
Line 55:		Line 55:
	== Key Regulatory Requirements ==		== Key Regulatory Requirements ==

	'''Ethical approval and informed consent''' are mandatory for all regulated trials. Institutional Review Board (IRB) or Ethics Committee (EC) approval must be obtained before trial initiation, and participants must sign an informed consent form (ICF) outlining risks, benefits, and rights.		'''Ethical approval and [[informed consent]]''' are mandatory for all regulated trials. Institutional Review Board (IRB) or [[Ethics]] Committee (EC) approval must be obtained before trial initiation, and participants must sign an informed consent form (ICF) outlining risks, benefits, and rights.

	'''Trial registration''' is required in public registries such as ClinicalTrials.gov (USA) or EudraCT (EU), to promote transparency and accountability.		'''Trial registration''' is required in public registries such as ClinicalTrials.gov (USA) or EudraCT (EU), to promote transparency and accountability.
Line 85:		Line 85:
	----		----

	~~See also~~:		=== Bibliography ===
	* [[~~Phases of Clinical Trials~~]]
	* [[~~Good Clinical Practice (GCP)~~]]		# Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. ''The Lancet''. 2002;359(9305):515–519.
	* [[~~CONSORT~~]]		# Altman DG, Bland JM. Statistics notes: how to randomise. ''BMJ''. 1999;319(7211):703–704.
	* [[Data Safety and Monitoring Board]]		# Moher D, Hopewell S, Schulz KF, et al. [[CONSORT]] 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. ''BMJ''. 2010;340:c869.
			# Piantadosi S. Clinical Trials: A Methodologic Perspective. 3rd ed. Wiley; 2017. Chapter 7: [[Randomization]] methods and implementation.
			# Higgins JPT, Thomas J, Chandler J, et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions, version 6.3 (updated February 2022). Cochrane; 2022. Chapter 8: Random sequence generation and [[allocation concealment]].

			----
			''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 19:35, 26 March 2025

2025-03-26T19:35:26Z

← Older revision		Revision as of 19:35, 26 March 2025
Line 69:		Line 69:
	== Challenges in Regulated Trials ==		== Challenges in Regulated Trials ==

	Regulated trials are often complex and resource-intensive		Regulated trials are often complex and resource-intensive. Regulatory requirements vary across countries, requiring harmonization for global studies. Phase 3 trials are particularly expensive and may take years to complete. Ethical dilemmas may arise when balancing innovation with participant safety.

			Recruitment and retention are persistent challenges, especially when trials require large, diverse populations. Ensuring representative enrollment and long-term follow-up can be difficult in real-world settings.

			== Examples of Major Regulated Trials ==

			* '''Pfizer-BioNTech COVID-19 Vaccine Trial''': Conducted under the FDA’s Emergency Use Authorization (EUA) pathway.
			* '''CAR-T Cell Therapy Trials''': Evaluated under the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation.
			* '''Apple Heart Study''': A wearable device trial that used decentralized digital trial methods for regulatory engagement.

			== Conclusion ==

			Regulated clinical trials are essential for ensuring the safety, efficacy, and quality of medical interventions. They play a critical role in advancing evidence-based healthcare while protecting public health. Although these trials are complex, costly, and time-consuming, they are foundational to drug and device development and remain the gold standard for regulatory approval.

			----

			See also:
			* [[Phases of Clinical Trials]]
			* [[Good Clinical Practice (GCP)]]
			* [[CONSORT]]
			* [[Data Safety and Monitoring Board]]

Lawrence: Created page with "= Regulated trials = A '''regulated trial''' is a clinical trial that is subject to the oversight of national or international regulatory authorities. These include agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and others. Regulated trials typically involve investigational drugs, biologics, medical devices, or advanced therapy medicinal products (ATMPs), and must comply with rigorous standards to ensure..."

2025-03-26T19:33:46Z

Created page with "= Regulated trials = A '''regulated trial''' is a clinical trial that is subject to the oversight of national or international regulatory authorities. These include agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and others. Regulated trials typically involve investigational drugs, biologics, medical devices, or advanced therapy medicinal products (ATMPs), and must comply with rigorous standards to ensure..."

New page

= Regulated trials =

A '''regulated trial''' is a clinical trial that is subject to the oversight of national or international regulatory authorities. These include agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and others. Regulated trials typically involve investigational drugs, biologics, medical devices, or advanced therapy medicinal products (ATMPs), and must comply with rigorous standards to ensure patient safety, ethical conduct, and data integrity.

== Key Regulatory Bodies and Guidelines ==

Regulatory requirements vary by region, but all are grounded in ethical principles and scientific rigor. The following table outlines key agencies and their guiding regulations:

{| class="wikitable"
! Regulatory Agency !! Jurisdiction !! Key Guidelines
|-
| FDA (Food and Drug Administration) || USA || 21 CFR 312 (Drugs), 21 CFR 812 (Devices)
|-
| EMA (European Medicines Agency) || European Union || Clinical Trials Regulation (EU CTR No 536/2014)
|-
| MHRA (Medicines and Healthcare products Regulatory Agency) || UK || UK Clinical Trials Regulations
|-
| Health Canada || Canada || Food and Drugs Act, Division 5
|-
| TGA (Therapeutic Goods Administration) || Australia || Australian Clinical Trial Handbook
|-
| ICH-GCP (International Council for Harmonisation – Good Clinical Practice) || Global || ICH E6 (GCP)
|}

These guidelines ensure that regulated trials meet internationally accepted standards of scientific validity, ethical conduct, and operational quality.

== Types of Regulated Trials ==

'''Drug trials''' are conducted to evaluate investigational new drugs (INDs) or new indications for approved drugs. These trials must be preceded by preclinical studies and follow a structured development path through clinical phases. Common examples include oncology drug trials and vaccine development.

'''Biologic trials''' focus on biological products such as monoclonal antibodies, gene therapies, and vaccines. These require a Biologics License Application (BLA) for approval and are often subject to stricter long-term safety monitoring. Examples include mRNA vaccines and CAR-T therapies.

'''Medical device trials''' are used to evaluate diagnostic or therapeutic devices like pacemakers, surgical robots, or wearable health monitors. In the U.S., they often require an Investigational Device Exemption (IDE) prior to human testing.

'''Advanced Therapy Medicinal Products (ATMPs)''' include cell therapies, gene therapies, and tissue-engineered products. Due to their complexity and potential for long-term effects, ATMP trials are heavily regulated and monitored.

== Phases of Regulated Trials ==

Drug and biologic trials typically follow four clinical phases:

{| class="wikitable"
! Phase !! Objective !! Sample Size !! Key Features
|-
| Phase 1 || Safety & Dosage || 20–100 participants || First-in-human studies, dose escalation, pharmacokinetics
|-
| Phase 2 || Efficacy & Safety || 100–500 patients || Early signs of efficacy, optimal dosing
|-
| Phase 3 || Confirmatory Efficacy || 1,000+ patients || Large-scale, multicenter randomized controlled trials
|-
| Phase 4 || Post-Marketing Surveillance || Real-world patients || Long-term safety, rare adverse events
|}

Medical device trials may follow different stages (e.g., Pilot, Pivotal, and Post-Market Surveillance), aligned with device-specific regulatory frameworks.

== Key Regulatory Requirements ==

'''Ethical approval and informed consent''' are mandatory for all regulated trials. Institutional Review Board (IRB) or Ethics Committee (EC) approval must be obtained before trial initiation, and participants must sign an informed consent form (ICF) outlining risks, benefits, and rights.

'''Trial registration''' is required in public registries such as ClinicalTrials.gov (USA) or EudraCT (EU), to promote transparency and accountability.

'''Good Clinical Practice (GCP) compliance''' ensures that trials follow international standards for data quality, participant protection, monitoring, and documentation. ICH-GCP (E6) is the most widely recognized global framework.

'''Adverse event and safety reporting''' is critical. Serious Adverse Events (SAEs) must be promptly reported to regulatory bodies. Many trials have a Data Safety Monitoring Board (DSMB) responsible for ongoing safety oversight.

'''Regulatory submissions''' are needed at various stages. Trials often begin with an IND or IDE application and culminate in a New Drug Application (NDA), Biologics License Application (BLA), or Premarket Approval (PMA) for devices.

'''Post-marketing surveillance''' (Phase 4) assesses real-world safety and effectiveness. Regulators may issue warnings, recall products, or restrict indications based on emerging data.

== Challenges in Regulated Trials ==

Regulated trials are often complex and resource-intensive